As vaccine hopes take centre stage, will value stocks regain favour among investors?
It seemed like the equation might be changing. Value stocks enjoyed a renaissance this month when vaccine euphoria prompted investors to rotate into shares trashed as the pandemic crimped the global economy. Their returns beat their growth counterparts by five percentage points in the first three weeks of November.